Jacob Barnett, 14-Year-Old With Asperger’s Syndrome, May Be Smarter Than Einstein.


When Jacob Barnett was 2 years old, he was diagnosed with moderate to severe autism. Doctors told his parents that the boy would likely never talk or read and would probably be forever unable to independently manage basic daily activities like tying his shoe laces.

But they were sorely, extraordinarily mistaken.

1238722_670379429649738_1196246017_n

Today, Barnett — now 14 — is a Master’s student, on his way to earning a PhD in quantum physics. According to the BBC, the teen, who boasts an IQ of 170, has already been tipped to one day win the Nobel Prize.

Since enrolling at Indiana University-Purdue University Indianapolis (IUPUI) at the age of 10, Barnett has flourished — astounding his professors, peers and family with his spectacular intelligence.

The teen tutors other college students in subjects like calculus and is a published scientific researcher, with an IQ that is believed to be higher than that of Albert Einstein. In fact, according to a 2011 TIME report, Barnett, who frequently tops his college classes, has asserted that he may one day disprove Einstein’s Theory of Relativity. (Watch him explain his genius to 60 minutes’ Morley Safer in a 2012 interview in the video above.)

Outside of his rigorous university commitments, Barnett, who has Asperger’s Syndrome, is also an entrepreneur and aspiring author

The teen, who, with his family, runs a charity called Jacob’s Place for kids on the spectrum, has used his story to raise awareness and dispel myths about autism.

“I’m not supposed to be here at all,” he said last year during a TEDx Teen speech about “forgetting what you know” in New York City. “You know, I was told that I wouldn’t talk. There’s probably a therapist watching who is freaking out right now.”

 

Though he makes it all look so easy,his mother, Kristine Barnett, says that he has to work hard on a daily basis to handle his autism.

“He overcomes it every day. There are things he knows about himself that he regulates everyday,” his mother told the Indianapolis Star last month.

In April, Kristine Barnett’s memoir about her family’s experience with autism, “The Spark: A Mother’s Story of Nurturing Genius,” was released. A movie deal is said to be in the works.

“I hope it really inspires children to actually be doing something,” Barnett told the Star of his mom’s book and potential film. “[I hope it] encourages them to do what they like doing. I just hope it is inspirational.”

For more on Jacob Barnett, watch this March 2013 YouTube video of him working through what is described as “a simple quantum mechanics problem“:

 

Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.


Valproate is used for the treatment of epilepsy and other neuropsychological disorders and may be the only treatment option for women of childbearing potential. However, prenatal exposure to valproate may increase the risk of autism.

OBJECTIVE: To determine whether prenatal exposure to valproate is associated with an increased risk of autism in offspring.
DESIGN, SETTING AND
PARTICIPANTS: Population-based study of all children born alive in Denmark from 1996 to 2006. National registers were used to identify children exposed to valproate during pregnancy and diagnosed with autism spectrum disorders (childhood autism [autistic disorder], Asperger syndrome, atypical autism, and other or unspecified pervasive developmental disorders). We analyzed the risks associated with all autism spectrum disorders as well as childhood autism. Data were analyzed by Cox regression adjusting for potential confounders (maternal age at conception, paternal age at conception, parental psychiatric history, gestational age, birth weight, sex, congenital malformations, and parity). Children were followed up from birth until the day of autism spectrum disorder diagnosis, death, emigration, or December 31, 2010, whichever came first. MAIN OUTCOMES AND MEASURES: Absolute risk (cumulative incidence) and the hazard ratio (HR) of autism spectrum disorder and childhood autism in children after exposure to valproate in pregnancy.
RESULTS: Of 655,615 children born from 1996 through 2006, 5437 were identified with autism spectrum disorder, including 2067 with childhood autism. The mean age of the children at end of follow-up was 8.84 years (range, 4-14; median, 8.85). The estimated absolute risk after 14 years of follow-up was 1.53% (95% CI, 1.47%-1.58%) for autism spectrum disorder and 0.48% (95% CI, 0.46%-0.51%) for childhood autism. Overall, the 508 children exposed to valproate had an absolute risk of 4.42% (95% CI, 2.59%-7.46%) for autism spectrum disorder (adjusted HR, 2.9 [95% CI, 1.7-4.9]) and an absolute risk of 2.50% (95% CI, 1.30%-4.81%) for childhood autism (adjusted HR, 5.2 [95% CI, 2.7-10.0]). When restricting the cohort to the 6584 children born to women with epilepsy, the absolute risk of autism spectrum disorder among 432 children exposed to valproate was 4.15% (95% CI, 2.20%-7.81%) (adjusted HR, 1.7 [95% CI, 0.9-3.2]), and the absolute risk of childhood autism was 2.95% (95% CI, 1.42%-6.11%) (adjusted HR, 2.9 [95% CI, 1.4-6.0]) vs 2.44% (95% CI, 1.88%-3.16%) for autism spectrum disorder and 1.02% (95% CI, 0.70%-1.49%) for childhood autism among 6152 children not exposed to valproate. CONCLUSIONS AND RELEVANCE: Maternal use of valproate during pregnancy was associated with a significantly increased risk of autism spectrum disorder and childhood autism in the offspring, even after adjusting for maternal epilepsy. For women of childbearing potential who use antiepileptic medications, these findings must be balanced against the treatment benefits for women who require valproate for epilepsy control.

Source: JAMA

 

Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. .


Valproate is used for the treatment of epilepsy and other neuropsychological disorders and may be the only treatment option for women of childbearing potential. However, prenatal exposure to valproate may increase the risk of autism.

OBJECTIVE: To determine whether prenatal exposure to valproate is associated with an increased risk of autism in offspring.
DESIGN, SETTING AND
PARTICIPANTS: Population-based study of all children born alive in Denmark from 1996 to 2006. National registers were used to identify children exposed to valproate during pregnancy and diagnosed with autism spectrum disorders (childhood autism [autistic disorder], Asperger syndrome, atypical autism, and other or unspecified pervasive developmental disorders). We analyzed the risks associated with all autism spectrum disorders as well as childhood autism. Data were analyzed by Cox regression adjusting for potential confounders (maternal age at conception, paternal age at conception, parental psychiatric history, gestational age, birth weight, sex, congenital malformations, and parity). Children were followed up from birth until the day of autism spectrum disorder diagnosis, death, emigration, or December 31, 2010, whichever came first. MAIN OUTCOMES AND MEASURES: Absolute risk (cumulative incidence) and the hazard ratio (HR) of autism spectrum disorder and childhood autism in children after exposure to valproate in pregnancy.
RESULTS: Of 655,615 children born from 1996 through 2006, 5437 were identified with autism spectrum disorder, including 2067 with childhood autism. The mean age of the children at end of follow-up was 8.84 years (range, 4-14; median, 8.85). The estimated absolute risk after 14 years of follow-up was 1.53% (95% CI, 1.47%-1.58%) for autism spectrum disorder and 0.48% (95% CI, 0.46%-0.51%) for childhood autism. Overall, the 508 children exposed to valproate had an absolute risk of 4.42% (95% CI, 2.59%-7.46%) for autism spectrum disorder (adjusted HR, 2.9 [95% CI, 1.7-4.9]) and an absolute risk of 2.50% (95% CI, 1.30%-4.81%) for childhood autism (adjusted HR, 5.2 [95% CI, 2.7-10.0]). When restricting the cohort to the 6584 children born to women with epilepsy, the absolute risk of autism spectrum disorder among 432 children exposed to valproate was 4.15% (95% CI, 2.20%-7.81%) (adjusted HR, 1.7 [95% CI, 0.9-3.2]), and the absolute risk of childhood autism was 2.95% (95% CI, 1.42%-6.11%) (adjusted HR, 2.9 [95% CI, 1.4-6.0]) vs 2.44% (95% CI, 1.88%-3.16%) for autism spectrum disorder and 1.02% (95% CI, 0.70%-1.49%) for childhood autism among 6152 children not exposed to valproate. CONCLUSIONS AND RELEVANCE: Maternal use of valproate during pregnancy was associated with a significantly increased risk of autism spectrum disorder and childhood autism in the offspring, even after adjusting for maternal epilepsy. For women of childbearing potential who use antiepileptic medications, these findings must be balanced against the treatment benefits for women who require valproate for epilepsy control.

Source: JAMA

 

 



 

Source: Nature